Ethical and Scientific Concerns Relating to CRISPR/Cas Gene Therapy
DOI:
https://doi.org/10.58445/rars.2460Keywords:
CRISPR, Ethics, Genome Editing, Off-Target Effects, Delivery MethodsAbstract
CRISPR is a genome editing tool that uses the Cas protein to edit genes. CRISPR has begun clinical trials in a few fields but there is still a lot of work to be done before the tool is ready. The main issues with CRISPR stem from the technical and ethical concerns. The technical concerns are primarily about off-target effects and inefficient delivery methods which can cause dangerous genetic mutations. Scientists are trying to remedy this issue through the further development of the Cas protein, improving guide RNA, and using in silico to predict where these issues may occur. Beyond the technical issues are the various ethical concerns that CRISPR stem from philosophical, theological, and social viewpoints. These varying viewpoints have their own beliefs on CRISPR but the common consensus disapproves of genetic enhancement through CRISPR due to fears of extreme inequality caused by its use. To remedy this many call for greater regulations placed on CRISPR and gene editing as a whole to ensure human safety. CRISPR has extreme potential in the field of biotechnology and can revolutionize how science and medicine is done for years to come, but before that can happen these important issues must be thoroughly addressed.
References
G, S., Ar, S., M, B., Ss, L., & C, C. (2021). CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Molecular Therapy : The Journal of the American Society of Gene Therapy, 29(2). https://doi.org/10.1016/j.ymthe.2020.09.028
Gabel, I., & Moreno, J. (2019). Genome Editing, Ethics, and Politics. AMA Journal of Ethics, 21(12), 1105–1110. https://doi.org/10.1001/amajethics.2019.1105
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11, 1143157. https://doi.org/10.3389/fbioe.2023.1143157
Henderson, H. (2019, December 17). Paying for CRISPR Cures: The Economics of Genetic Therapies. Innovative Genomics Institute (IGI). https://innovativegenomics.org/news/paying-for-crispr-cures/
Joseph, A. M., Karas, M., Ramadan, Y., Joubran, E., & Jacobs, R. J. (n.d.). Ethical Perspectives of Therapeutic Human Genome Editing From Multiple and Diverse Viewpoints: A Scoping Review. Cureus, 14(11), e31927. https://doi.org/10.7759/cureus.31927
Kantor, A., McClements, M. E., & MacLaren, R. E. (2020). CRISPR-Cas9 DNA Base-Editing and Prime-Editing. International Journal of Molecular Sciences, 21(17), 6240. https://doi.org/10.3390/ijms21176240
LI, C., BRANT, E., BUDAK, H., & ZHANG, B. (2021). CRISPR/Cas: A Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. Journal of Zhejiang University. Science. B, 22(4), 253–284. https://doi.org/10.1631/jzus.B2100009
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020). Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing. Cells, 9(7), 1608. https://doi.org/10.3390/cells9071608
Sibbald, B. (2001). Death but one unintended consequence of gene-therapy trial. CMAJ: Canadian Medical Association Journal, 164(11), 1612.
Downloads
Posted
Categories
License
Copyright (c) 2025 Aashrith Adabala

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.